Emergent BioSolutions Inc. (NYSE:EBS) Director Sells $204,050.00 in Stock

Emergent BioSolutions Inc. (NYSE:EBS) Director Neal Franklin Fowler sold 35,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now directly owns 101,100 shares of the company’s stock, valued at $589,413. The trade was a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Emergent BioSolutions Stock Performance

NYSE EBS opened at $5.74 on Friday. The company has a market cap of $311.62 million, a P/E ratio of -1.40 and a beta of 1.80. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The stock has a 50-day moving average of $8.92 and a two-hundred day moving average of $8.82. Emergent BioSolutions Inc. has a 1-year low of $1.82 and a 1-year high of $15.10.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million during the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the previous year, the company posted ($0.77) EPS. As a group, analysts anticipate that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Hedge Funds Weigh In On Emergent BioSolutions

Several institutional investors have recently bought and sold shares of the company. State Street Corp grew its position in shares of Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP acquired a new position in shares of Emergent BioSolutions during the third quarter worth about $9,296,000. Millennium Management LLC grew its position in shares of Emergent BioSolutions by 83.0% during the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after buying an additional 671,947 shares in the last quarter. Invesco Ltd. grew its position in shares of Emergent BioSolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after buying an additional 638,995 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Emergent BioSolutions by 67.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after buying an additional 444,790 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on EBS shares. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, March 4th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.